Health ❯ Healthcare

Drug Approval

FDA FDA Regulations Regulatory Affairs FDA Approval Clinical Trials Regulatory Agencies Regulatory Bodies Marketing Authorization European Medicines Agency Regulatory Process

FDA Grants Accelerated Approval to Sonrotoclax for Relapsed Mantle Cell Lymphoma

The move offers patients who failed BTK inhibitor therapy a new BCL2 option with early signs of durable response.

Lilly Shares Slip as Foundayo’s Second-Week Prescriptions Trail Wegovy

Single CAR T Infusion Clears Residual Disease in High-Risk Smoldering Myeloma Trial

GSK Gains After Cramer Endorsement as Company Pushes Into Weight-Loss Drugs

Summit Therapeutics Shares Rally as Ivonescimab Trials Near Q2 Readout

FDA Proposes ‘Plausible Mechanism’ Pathway for Individualized Rare-Disease Therapies

Pfizer to Commercialize Sciwind’s GLP-1 Ecnoglutide in China Under Exclusive License

Biogen Guides 2026 Profit Above Estimates on Cost Cuts and Leqembi Momentum

Epcoritamab Improves PFS but Not OS in Phase 3 DLBCL Trial

Alumis TYK2 Pill Hits Phase 3 Goals in Psoriasis as Stock Jumps and $175 Million Offering Is Planned

FDA Approves Vanda’s Nereus, First New Motion Sickness Treatment in Over 40 Years

FDA Grants Accelerated Approval to Subcutaneous Lunsumio for Relapsed Follicular Lymphoma

FDA Approves Epkinly Monotherapy and Triplet Regimen for Relapsed Follicular Lymphoma

Roche Says Breast Cancer Pill Cuts Recurrence in Phase 3 Adjuvant Trial

FDA Approves Komzifti, First Menin Inhibitor for Relapsed NPM1‑Mutant AML

FDA Approves Poherdy as First Interchangeable Biosimilar to Perjeta for HER2-Positive Breast Cancer

FDA Approves Darzalex Faspro as First Therapy for High-Risk Smoldering Multiple Myeloma

BioNTech Raises 2025 Sales Outlook After $1.5 Billion BMS Payment

FDA Reapproves GSK’s Blenrep for Multiple Myeloma in Narrow Combination Use

J&J Myeloma Trial Stopped Early After Tecvayli–Darzalex Shows PFS and OS Benefit